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Background: Chemotherapy improves survival for many patients with SCLC, and hence it is important to understand variations in
practice and outcomes for this treatment strategy.
Methods:We used the National Lung Cancer Audit and Hospital Episodes Statistics to determine the proportion of patients who
received chemotherapy for SCLC, and assess the effects of patient and organisational factors on the odds of receiving
chemotherapy and of completing four cycles. We calculated median survival and used Cox regression to determine factors that
predicted survival.
Results: Of 15 091 cases of SCLC, 70% received at least one cycle of chemotherapy. More deprived people were less likely to
receive chemotherapy, but patients were more likely to receive chemotherapy, and to complete Xfour cycles, if they were
referred to the lung cancer team by their GP. Median survival for those treated with chemotherapy was 12.9 months for limited and
7.3 months for extensive stage disease.
Conclusions: The Linked NLCA and HES data provide real-life measures of survival in people treated with chemotherapy and
show how this is influenced by patient and tumour characteristics. These data show the characteristics of patients who are less
likely to complete a full course of treatment, an adverse predictor of survival.
The mainstay of treatment for people with small-cell lung cancer
(SCLC) is chemotherapy. The results of clinical trials show that
treatment with a platinum agent combined with etoposide can
result in a median survival of 8–12 months for people with
extensive stage disease (Fukuoka et al, 1991; Roth et al, 1992;
Sundstrøm et al, 2002), and up to 27 months for those with
limited stage disease, particularly when combined with radio-
therapy (Turrisi et al, 1999; Sundstrøm et al, 2002; Takada et al,
2002). As trials tend to include younger patients with relatively
good performance status, the median survival for the full
spectrum of patients is likely to be less.
Inequalities in access to surgery for people with lung cancer have
been documented (Rich et al, 2011a), and it is possible that these
also exist in treatments for SCLC. It is important to determine
whether chemotherapy treatment rates vary by individual patient
factors and/or organisational factors and the English National Lung
Cancer Audit (NLCA) is a valuable resource in this context.
Data from clinical trials suggest thatB75% of patients complete
the intended number of chemotherapy cycles (Singh et al, 2005),
but we do not know the proportion of patients in routine clinical
practice for whom this is the case. An understanding of the
characteristics of this group of patients could also help clinicians
identify people for whom the risks of starting chemotherapy may
outweigh the benefits.
We used the English National Lung Cancer Audit (NLCA) to
describe the characteristics of patients with SCLC who received
chemotherapy and those who went on to complete a full course.
We quantified overall survival from diagnosis and following
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chemotherapy according to the patient characteristics and the
number of cycles completed.
MATERIALS AND METHODS
Data sources and study population. We identified cases of
histologically confirmed SCLC diagnosed between 1 January 2006
and 31 September 2011 using the English NLCA database (Health
and Social Care Information Centre, 2013); patients who had
undergone surgery were excluded. We used linked data from
Hospital Episodes Statistics (HES), which cover all inpatient
hospital care, to provide additional information on co-morbidity
and chemotherapy treatment, and from the Office for National
Statistics (ONS) to provide dates of registered deaths.
Chemotherapy. We assessed first-line chemotherapy treatment by
including any chemotherapy given in the first 6 months after a
patient’s diagnosis. Following an assessment of validity of
chemotherapy records in the two databases (Powell et al, 2013),
people who received chemotherapy were identified using both the
NLCA and HES. The NLCA records the date of the first dose of
chemotherapy but every time a chemotherapy dose is delivered in a
hospital inpatient setting this is captured in HES. For patients with
chemotherapy records in HES, we extracted the number of cycles
received. We defined a full course of chemotherapy as Xfour
cycles based on current UK recommendations (National Institute
for Health and Clinical Excellence, 2011.
Treatment data entered into the NLCA and HES up to 31
March 2012 were available to us, hence all patients had at least 6
months after their diagnosis where records of chemotherapy could
be identified, although some patients died before this.
Covariates. We used our established method to calculate a
Charlson co-morbidity index using diagnoses recorded in inpatient
HES episodes, which started any time before the date of lung
cancer diagnosis (Charlson et al, 1987; Rich et al, 2011b); this was
analysed in four categories (0, 1, 2–3 andX4). All other covariates
were obtained from the NLCA: socio-economic status measured by
postcode-derived Townsend index (in quintiles); World Health
Organisation performance status (PS); route of referral to the lung
cancer specialist (classified as listed in Table 1); and stage which
was almost always recorded as limited or extensive but for the few
cases where the more recent Tumour Node Metastases staging
system was used we converted this to limited (T1-4, N0-3, M0) or
extensive (M1a/b) as appropriate (Union for International Cancer
Control, 2009). We also used NLCA variables to define cases who
received chemo-radiotherapy as those who had a record of either
radical radiotherapy or chemo-radiotherapy within 6 months of
diagnosis.
The NLCA records the trust at which the patient is first seen
and the trust of their chemotherapy treatment, which is often but
not always the same. We defined chemotherapy trusts as those
trusts that administered chemotherapy themselves in X75% of
their treated cases (i.e., they did not have to refer their patients to
another trust for chemotherapy). We chose 75% as the cutoff after
inspecting the distribution of this variable (Supplementary Figure A)
but also performed sensitivity analyses usingX50% and X90% as
cutoffs.
Statistical methods. All analyses were performed using Stata v12
(StataCorp, TX, USA). We calculated the proportion of people who
had chemotherapy according to the patient, tumour and trust
characteristics defined above and used multivariate logistic
regression to estimate the odds of receiving chemotherapy
according to the same characteristics. For those who received
chemotherapy, we estimated the odds of receiving four or more
cycles (representing a completed course of chemotherapy) and also
how this was associated with time to treatment and receipt of
chemo-radiotherapy. We used a binary variable for time to
treatment using above or below the median number of days from
diagnosis to first chemotherapy dose.
We plotted Kaplan–Meier survival curves and calculated
median survival from the date of diagnosis for people with limited
and extensive stage disease, according to the number of cycles of
chemotherapy given in the 6 months after diagnosis. If date of
diagnosis was missing this was closely approximated using other
dates as we have described previously (Khakwani et al, 2013). To
remove the effect of immortal time bias, we also assessed survival
from date of finishing chemotherapy treatment. Patients were
followed up to death, or they were censored on 31 March 2013, the
date of ONS death tracing for this study.
We used Cox regression to estimate survival from the date of
diagnosis according to whether or not chemotherapy or chemo-
radiotherapy were given, route of referral and whether or not the
patient was first seen in a chemotherapy trust. Hazard ratios were
calculated for each of these adjusting for age, sex, performance
status, co-morbidity and stage. We also estimated survival
following the end of the last chemotherapy cycle according to
the number of cycles given (1–3 or X4), time from diagnosis to
treatment and trust first seen. We sought interactions between
stage and all other variables in the effect on survival and checked
the proportional hazards assumption in our data by inspecting
Nelson–Aalen plots.
RESULTS
We identified 15 724 people with histologically confirmed SCLC
diagnosed between 1 January 2006 and 30 September 2011. We
excluded 289 people who had surgery and 119 with a recorded
treatment date before their diagnosis or after death. Trusts in one
specific geographical area had an extremely high proportion of
patients (65%) with no record of chemotherapy. We believe this to
have been a systematic error in data entry and excluded the 225
patients first seen in this group of trusts, leaving 15 091 people
(96% of the original SCLC population) for analysis.
The mean age at diagnosis was 68 years (s.d. 9.7 years); 55% had
extensive stage disease at presentation (although stage was not
recorded in 20% of cases) and more were in the most deprived
Townsend quintile than any other (25% in quintile 5) (Table 1).
Seventy-three percent of patients (n¼ 11 032) were first seen at one
of the 94 chemotherapy trusts; the 53 non-chemotherapy trusts
first saw 27% of this population.
Chemotherapy. Seventy percent of patients had a record of
chemotherapy; 790 (7%) of these also had a record that was
consistent with concurrent or sequential chemo-radiotherapy
(Table 1). Within the 10 582 cases treated with chemotherapy,
the median time from diagnosis to initiation of treatment was 18
days (IQR 12–27) and this did not change between 2006 (19 days
(13–29)) and 2011 (18 days (11–26)). For patients who first
presented to a chemotherapy trust, the median time to chemother-
apy was 18 days (12–27), whereas for those who presented to non-
chemotherapy trusts this was 19 days (12–26).
After adjusting for other factors, patients were more likely to
have chemotherapy if they were younger, had good performance
status, limited stage disease and a low co-morbidity index
(Table 1). People living in more socio-economically deprived areas
were less likely to be treated (likelihood ratio test for trend across
Townsend quintiles in adjusted analysis P¼ 0.0002) and compared
with those referred by a general practitioner (GP) those referred to
secondary care by any other route were less likely to get
chemotherapy, even after adjusting for other patient features.
(Table 1).
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Table 1. Features of patients who had chemotherapy and odds ratios for receiving chemotherapy
Total
N¼15091 %
Had
chemotherapy
n¼10582
(70%) % OR 95% CI
Adjusted
ORa 95% CI
Sex
Female 7126 47.2 5021 70.5 1.00 1.00
Male 7965 52.8 5561 69.8 0.97 0.90–1.04 0.98 0.91–1.07
Age group
o55 1204 8.0 1,043 86.6 2.76 2.30–3.32 2.29 1.87–2.80
55–59 1567 10.4 1,314 83.9 2.22 1.89–2.59 1.88 1.58–2.23
60–64 2378 15.8 1,923 80.9 1.80 1.58–2.05 1.73 1.49–1.99
65–69 2766 18.3 2133 77.1 1.44 1.28–1.62 1.38 1.20–1.57
70–74 2856 18.9 2002 70.1 1.00 1.00
75–79 2384 15.8 1435 60.2 0.65 0.58–0.72 0.63 0.56–0.72
80–84 1380 9.1 610 44.2 0.34 0.30–0.39 0.34 0.29–0.40
X85 556 3.7 122 21.9 0.12 0.10–0.15 0.12 0.09–0.15
Townsend quintile
1 (Least deprived) (socio-economic status) 2111 14.0 1499 71.0 1.00 1.00
2 2704 17.9 1926 71.2 1.01 0.89–1.15 0.96 0.83–1.11
3 2958 19.6 2083 70.4 0.97 0.86–1.10 0.94 0.81–1.09
4 3307 21.9 2310 69.9 0.95 0.84–1.07 0.82 0.71–0.94
5 (Most deprived) 3738 24.8 2631 70.4 0.97 0.86–1.09 0.83 0.72–0.96
Missing 273 1.8 133 48.7 0.39 0.30–0.50 0.43 0.32–0.58
Performance status
0 2121 14.1 1909 90.0 1.00 1.00
1 4494 29.8 3844 85.5 0.66 0.56–0.77 0.86 0.72–1.02
2 3072 20.4 2094 68.2 0.24 0.20–0.28 0.40 0.33–0.47
3 2017 13.4 822 40.8 0.08 0.06–0.09 0.14 0.12–0.17
4 567 3.8 68 12.0 0.02 0.01–0.02 0.03 0.02–0.04
Missing 2820 18.7 1845 65.4 0.21 0.18–0.25 0.31 0.26–0.37
Charlson co-morbidity index
0 4899 32.5 3986 81.4 1.00 1.00
1 2644 17.5 1996 75.5 0.71 0.63–0.79 0.89 0.78–1.02
2–3 1987 13.2 1351 68.0 0.49 0.43–0.55 0.73 0.63–0.83
43 5561 36.8 3249 58.4 0.32 0.29–0.35 0.53 0.48–0.59
Stage
Extensive 8293 55.0 5474 66.0 1.00 1.00
Limited 3845 25.5 3130 81.4 2.25 2.05–2.47 1.63 1.46–1.83
Missing 2953 19.6 1978 67.0 1.04 0.96–1.14 1.01 0.91–1.13
Route of referral
Emergency admission 2323 15.4 1355 58.3 0.41 0.37–0.45 0.68 0.60–0.77
General practitioner 7267 48.2 5624 77.4 1.00 1.00
Consultant referral 2729 18.1 1869 68.5 0.63 0.58–0.70 0.91 0.81–1.02
Other (inc private) 887 5.9 589 66.4 0.58 0.50–0.67 0.73 0.61–0.87
Emeergency department 1120 7.4 630 56.3 0.38 0.33–0.43 0.60 0.51–0.70
Missing 765 5.1 515 67.3 0.60 0.51–0.71 0.79 0.66–0.96
Trust first seen
Non-chemotherapy trust 4031 26.7 2673 66.3 1.00 1.00
Chemotherapy trust 11032 73.1 7893 71.5 1.25 1.16–1.35 1.39 1.27–1.52
Missing or trust which saw o20 cases 28 0.2 16 57.1 0.88 0.45–1.75 0.69 0.31–1.52
Abbreviations: CI¼ confidence interval; OR¼odds ratio.
aAdjusted for all other variables.
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For patients first seen at a chemotherapy trust, the odds of being
treated with chemotherapy were increased by 39% compared with
patients seen at non-chemotherapy trusts (adjusted OR 1.39
(1.27–1.52) (Table 1). This difference persisted when we used
X90% (adjusted OR 1.18 (1.08–1.28)) and X50% (adjusted OR
1.43 (1.30–1.58)) as the cutoff values for defining a chemotherapy
trust.
Chemotherapy cycles. The proportions of people who received 0,
1–2, 3, 4–5 and X6 cycles of chemotherapy are shown in Table 2.
In 12% of cases, chemotherapy was only recorded in the NLCA
records and hence we were not able to assess the number of cycles
given. These patients are identified in the tables as ‘NLCA only’. Of
those with HES chemotherapy data, 63% received a X4-cycle
course of chemotherapy.
Increasing age, PS, stage and co-morbidity score, and the GP
route of referral were independently associated with increased odds
of completing chemotherapy compared with any other referral
method, as was a diagnosis to treatment interval of o18 days
compared with those who waited longer. People who had chemo-
radiotherapy were more likely to complete X4 cycles of
chemotherapy even after adjusting for patient characteristics as
shown in Table 3.
Survival. Median survival from time of diagnosis for all patients
(N¼ 15 091) was 6.2 months (IQR 1.5–12.4); this was 11.2 months
(5.4–20.3) and 4.2 months (1.1–9.3) for people with limited and
extensive stage disease, respectively. Median survival by stage
according to the number of chemotherapy cycles received is shown
in Table 2.
Figure 1 shows survival from the date of diagnosis according to
the number of cycles received and stage at presentation. People
who received one or two cycles are grouped together, as are those
who received four or five cycles because their survival curves were
almost identical. Figure 2 shows the same survival analysis but
from the end of the last chemotherapy cycle.
The Cox regression analysis from time of diagnosis showed that
for people who completed chemotherapy the risk of death was 75%
lower than for those who received no chemotherapy (adjusted HR
0.25, 95% CI: 0.24–0.27) (Table 4).
Survival did not vary significantly by Townsend quintile
or according to whether the patient was first seen at a
chemotherapy trust. People diagnosed with SCLC as a result of
an emergency admission were more likely to die than people
referred by their GP (HR 1.69, 95% CI 1.61–1.78); this
association was attenuated but not fully explained by age, sex,
PS, stage and co-morbidity index (adjusted HR 1.30, 95% CI
1.23–1.37). Those who waited X18 days between diagnosis and
treatment had a lower risk of dying compared with those who
waited o18 days (adjusted HR 0.84, 95% CI 0.81–0.88). There
was no evidence that stage modified the effect of any of the
variables on survival, and there was no evidence to reject our
proportional hazards assumption.
The results were very similar when we excluded the effect of
immortal time bias by assessing survival in those who had
chemotherapy from the end of their last recorded cycle
(Supplementary Table A).
DISCUSSION
We have used current English data to describe which patients with
SCLC received chemotherapy treatment and give real-life estimates
of survival. We found evidence that a patient’s chances of receiving
and/or completing chemotherapy treatment was related not only to
their fitness but also socio-economic status, the trust at which they
were first seen, the time taken from diagnosis to first treatment and
their route of referral to a lung cancer specialist.
Strengths and limitations. The main strengths of this study are
the large sample size and the validity of the database (Rich et al,
2011b). The NLCA estimates 98% case ascertainment since 2009
and completeness of individual data fields improves year on year
(NHS Information Centre, 2012). Mortality data from the ONS
ensured that our outcome data were both accurate and complete.
We enhanced our chemotherapy records by comparing records in
HES and the NLCA and found that use of a single data set
underestimated the proportion of people who received chemother-
apy. Inpatient HES data do not capture the majority of
radiotherapy episodes, and therefore we relied solely on the NLCA
for radiotherapy data and may have underestimated the number of
patients treated.
The main limitations of the study are the lack of detailed trust
level data, and the limited number of years available at present.
We were not able to draw conclusions as to whether six cycles of
treatment are better than four cycles and did not assess second line
or ongoing therapy. There is currently no consensus on how
patients who relapse, or do not completely respond, after first-line
treatment should be managed, although there is some evidence that
second-line therapy with the same agents is worthwhile (National
Institute for Health and Clinical Excellence, 2011); novel agents are
under investigation. The recently introduced systemic anticancer
therapy data set (National Cancer Intelligence Network (hosted by
Public Health England), 2011), linked with the NLCA will provide
Table 2.Median survival in days according to stage and number of cycles
of chemotherapy
Cycles
No. of
patients
(%)
N¼15091
Median
survival
from
diagnosis
(IQR)
No. of
patients
(%)
N¼7866a
Median survival
from
completing
chemotherapy
(IQR)
Overall
0 4509 (29.9) 30 (14–74)
1-2 2320 (15.4) 85 (43–185) 1595 (20.2) 70 (24–191)
3 908 (6.0) 209 (125–377) 818 (10.4) 126 (50–300)
4-5 3072 (20.4) 316 (213–527) 3000 (38.1) 189 (95–405)
Z6 2468 (16.4) 377 (270–612) 2453 (31.2) 224 (114–453)
NLCA
onlyb
1814 (12.0) 230 (78–396)
Extensive stage (N¼8293) 3972
0 2891 (34.0) 26 (12–56)
1-2 1399 (16.9) 73 (40–149) 925 (23.8) 53 (20–126)
3 439 (5.3) 163 (108–276) 386 (9.7) 82 (31–192)
4-5 1432 (17.3) 260 (187–384) 1391 (35.0) 135 (68–256)
6 1280 (15.4) 324 (247–485) 1270 (32.0) 168 (88–333)
NLCA
onlyb
924 (11.1) 177 (52–315)
Limited stage (N¼3845) 2066
0 715 (18.6) 79 (25–218)
1-2 465 (12.0) 141 (58–366) 346 (16.7) 134 (50–383)
3 295 (7.7) 301 (177–552) 276 (13.3) 213 (97–461)
4-5 1112 (28.9) 420 (280–758) 1098 (53.1) 300 (154–648)
6 777 (20.2) 505 (342–843) 774 (37.5) 347 (183–690)
NLCA
onlyb
484 (12.6) 356 (199–586)
aExcludes 4509 patients who did not receive chemotherapy, 1814 NLCA only, and 902 who
died within 21 days of starting a chemotherapy cycle.
bNLCA only: record of chemotherapy but insufficient data to calculate number of cycles.
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Table 3. Factors associated with completing X4 cycles in patients who started chemotherapy
Total
N¼8768a %
Received
X4 cycles
N¼5540
(63%) %
OR for
completing
X4 cycles 95% CI
Adjusted
ORb 95% CI
Sex
Female 4166 47.5 2641 63.4 1.00 1.00
Male 4602 52.5 2899 63.0 0.98 0.90–1.07 0.99 0.91–1.09
Age group
o55 895 10.2 618 69.1 1.41 1.19–1.68 1.29 1.07–1.54
55–59 1106 12.6 755 68.3 1.36 1.16–1.60 1.26 1.07–1.49
60–64 1620 18.5 1058 65.3 1.19 1.03–1.38 1.15 0.99–1.34
65–69 1777 20.3 1169 65.8 1.22 1.06–1.40 1.21 1.05–1.40
70–74 1625 18.5 995 61.2 1.00 1.00
75–79 1147 13.1 645 56.2 0.81 0.70–0.95 0.83 0.71–0.98
80–84 496 5.7 244 49.2 0.61 0.50–0.75 0.63 0.52–0.78
X85 102 1.2 56 54.9 0.77 0.52–1.15 0.80 0.53–1.21
Townsend quintile (socio-economic status)
1 (Least deprived) 1241 14.2 801 64.5 1.00 1.00
2 1590 18.1 1032 64.9 1.02 0.87–1.19 0.99 0.84–1.16
3 1743 19.9 1102 63.2 0.94 0.81–1.10 0.93 0.80–1.09
4 1932 22.0 1213 62.8 0.93 0.80–1.08 0.90 0.77–1.05
5 (Most deprived) 2152 24.5 1348 62.6 0.92 0.80–1.07 0.89 0.76–1.04
Missing 110 1.3 44 40.0 0.37 0.25–0.55 0.37 0.25–0.56
Performance status
0 1626 18.5 1243 76.4 1.00 1.00
1 3208 36.6 2168 67.6 0.64 0.56–0.74 0.71 0.62–0.82
2 1664 19.0 903 54.3 0.37 0.31–0.42 0.45 0.38–0.52
3 683 7.8 279 40.8 0.21 0.18–0.26 0.27 0.22–0.33
4 53 0.6 20 37.7 0.19 0.11–0.33 0.23 0.13–0.41
Missing 1534 17.5 927 60.4 0.47 0.40–0.55 0.56 0.48–0.66
Charlson co-morbidity index
0 3318 37.8 2298 69.3 1.00 1.00
1 1641 18.7 1076 65.6 0.85 0.75–0.96 0.93 0.81–1.05
2-3 1092 12.5 669 61.3 0.70 0.61–0.81 0.81 0.70–0.94
43 2717 31.0 1497 55.1 0.54 0.49–0.61 0.69 0.62–0.77
Stage
Extensive 4550 51.9 2712 59.6 1.00 1.00
Limited 2646 30.2 1889 71.4 1.69 1.53–1.87 1.44 1.29–1.61
Missing 1572 17.9 939 59.7 1.01 0.89–1.13 0.95 0.84–1.08
Time to treatment
o18 days 4305 49.1 2773 64.4 1.00 1.00
X18 days 4463 50.9 2767 62.0 0.90 0.83–0.98 0.81 0.74–0.89
Route of referral
Emergency admission 1157 13.2 626 54.1 0.56 0.49–0.64 0.68 0.59–0.78
General Practitioner 4666 53.2 3166 67.9 1.00 1.00
Consultant referral 1556 17.7 950 61.1 0.74 0.66–0.84 0.85 0.75–0.97
Other (inc private) 464 5.3 282 60.8 0.73 0.60–0.89 0.80 0.66–0.98
Emergency Department 514 5.9 269 52.3 0.52 0.43–0.63 0.63 0.52–0.77
Missing 411 4.7 247 60.1 0.71 0.58–0.88 0.82 0.66–1.01
Trust first seen
Non-chemotherapy trust 2064 23.5 1260 61.0 1.00 1.00
Chemotherapy trust 6688 76.3 4271 63.9 1.13 1.02–1.25 1.14 1.03–1.27
Missing/trust which saw o20 cases 16 0.2 9 56.3 0.82 0.30–2.21 0.63 0.23–1.72
Radiotherapy
No chemo-radiotherapy 7978 91.0 4919 61.7 1.00 1.00
Chemo-radiotherapy 790 9.0 621 78.6 2.29 1.92–2.72 1.74 1.44–2.09
Abbreviations: CI¼ confidence interval; OR¼odds ratio
aAnalysis restricted to people with SCLC who had record of chemotherapy in the Hospital Episodes Statistics databasel.
bAdjusted for age, sex, socio-economic status, co-morbidity index, performance status and stage.
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more detailed real-life data, which will help us to address these
important questions.
Comparison with trial data. Although we recognise that our
assessment of chemotherapy within observational population-
based data cannot be used to directly assess effectiveness,
comparisons with trial data are valuable.
Number of cycles. There are few studies examining the number of
cycles of chemotherapy actually given for SCLC outside of clinical
trials. Burgers et al (2002) found no significant difference in the
proportion of patients who received four or more cycles of
chemotherapy within a trial (49/60) compared with outside of a
trial (35/46) in their UK hospital. However, they only included
patients who were eligible for one of these two SCLC chemo-
therapy trials.
We chose four cycles to represent a complete course of
chemotherapy, but acknowledge that practice differs in this
respect. We found median survival to be longer after completion
of six or more cycles of chemotherapy compared with four to five
cycles, but cannot conclude that six cycles are preferable to four as
we do not have data on the fitness of the patients at the point of
finishing four cycles or reasons for discontinuing treatment.
Survival. Median survival for 105 people with limited stage SCLC
treated with etoposide and carboplatin in a randomised trial by the
Norwegian Lung Cancer Study Group was 14.5 months from
diagnosis and 8.4 months for 113 people with extensive stage
(Sundstrøm et al, 2002). This is similar for patients in our study
(12.9 and 7.3 months).
In our study, 71% of patients with limited stage who started
chemotherapy and 60% of those with extensive stage received four
or more cycles. This is lower than in the Norwegian trial where
70% of patients overall received five cycles; patients treated with
chemotherapy in that trial were fitter and younger than those in
the NLCA (median age 64 vs 67 years).
Clinical relevance
Route of referral. Those who were diagnosed as a result of an
emergency hospital attendance were less likely to start chemotherapy,
less likely to complete a course and less likely to survive than those
referred by a GP, even after adjusting for patient fitness and stage.
There is likely to be an element of residual confounding by patient
fitness in these estimates, but other studies have also found this
group to have poor survival (Elliss-Brookes et al, 2012; McPhail
et al, 2013). Given that almost a fifth of our patients presented by
an emergency route (which is similar to or lower than other
estimates for lung cancer overall in the United Kingdom
(Elliss-Brookes et al, 2012)), this is an extremely important group
for UK clinicians to target if overall survival from lung cancer is to
improve.
Time to initiation of treatment. The average time from diagnosis
to first chemotherapy dose was 18 days with 25% of patients
waiting more than 27 days. A period of longer than 18 days was
associated with improved survival, and this is likely to reflect the
impact of prioritising patients who are unwell with aggressive
disease and poor performance status.
Those potentially fitter patients who waited longer than 18 days
were less likely to complete four cycles of chemotherapy than those
who were treated more quickly. Completing X4 cycles was a
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Figure 2. Kaplan–Meier plots showing survival after final
chemotherapy cycle by number of cycles recorded, for limited and
extensive stage small-cell lung cancer.
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Figure 1. Kaplan–Meier plots showing survival after diagnosis by
number of cycles recorded, for limited and extensive stage small-cell
lung cancer.
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strong predictor of better survival; however, the direction of
causation is very uncertain and it may well be that non-completion
of chemotherapy is due to death, rather than the other way around.
Despite this uncertainly we would suggest that earlier treatment for
all may improve survival. The 2011 UK guidelines on SCLC
recommend that all patients are assessed by an oncologist within a
week of deciding to recommend treatment (National Institute for
Health and Clinical Excellence, 2011).
Trust features. People first seen at chemotherapy trusts did not
survive longer than those seen at non-chemotherapy trusts despite
being more likely to receive chemotherapy. Of patients first seen at
a non-chemotherapy trust 66.3% had chemotherapy compared
with 71.5% of those seen a chemotherapy trust. It is possible that
treating an average of 5% more of their patients was not enough to
translate into an overall survival benefit for chemotherapy trusts,
but also that the additional patients treated were less fit and higher
risk in ways that are difficult to measure.
CONCLUSION
These national data reflect the decisions that were made
about chemotherapy treatment in clinical practice in England.
We have provided real-life measures of survival in those treated
with chemotherapy taking into account patient and tumour
characteristics and have described which patients were less likely
to complete a full course of treatment based on key socio-
demographic and clinical features. We were unable to determine
whether six cycles of treatment are better than four cycles due to
the influence of immortal time bias and a lack of longitudinal data
on patient fitness and reasons for stopping treatment.
There is variation in the time from diagnosis to initiation of
treatment, and some evidence of inequalities in access to treatment
with particularly poor outcomes for those who present via the
emergency route. This further supports the need for initiatives that
improve early presentation and diagnosis. Our finding that
Table 4. Hazard ratios for death (analysis from time of diagnosis)
Survival from
diagnosis
Total
patients
N¼15091
Deaths
n¼10041 % HR 95% CI
Adjusted
HRa 95% CI
Townsend quintile
1 (Least deprived) 2111 1981 93.8 1.00 1.00
2 2704 2558 94.6 1.02 0.96–1.08 1.03 0.98–1.10
3 2958 2788 94.3 1.02 0.96–1.08 1.01 0.95–1.07
4 3307 3109 94.0 1.01 0.95–1.06 1.03 0.98–1.09
5 (Most deprived) 3738 3517 94.1 0.99 0.94–1.05 1.02 0.96–1.08
Missing 273 262 96.0 1.69 1.49–1.93 1.39 1.22–1.58
Route of referral
Emergency admission 2323 2246 96.7 1.69 1.61–1.78 1.30 1.24–1.37
General Practitioner 7267 6738 92.7 1.00 1.00
Consultant referral 2729 2566 94.0 1.19 1.14–1.25 1.01 0.96–1.06
Other (inc private) 887 836 94.3 1.18 1.10–1.27 1.03 0.96–1.11
Emergency Department 1120 1086 97.0 1.66 1.56–1.77 1.29 1.21–1.37
Missing 765 743 97.1 1.26 1.17–1.36 1.12 1.04–1.21
Radiotherapy
No chemotherapy 4509 4448 98.6 1.00 1.00
Chemotherapy only 9590 8962 93.5 0.28 0.27–0.29 0.35 0.34–0.37
Chemo-radiotherapy 992 805 81.1 0.16 0.15–0.18 0.26 0.24–0.28
Chemotherapy cycles
No chemotherapy 4509 4448 98.6 1.00 1.00
1–3 cycles 3228 3115 96.5 0.45 0.43–0.47 0.54 0.52–0.57
X4 cycles 5540 4936 89.1 0.20 0.19–0.21 0.25 0.24–0.27
NLCA record only 1814 1716 94.6 0.31 0.29–0.33 0.39 0.37–0.41
Time to treatment
o18 days 5137 4834 94.1 1.00 1.00
X18 days 5445 4933 90.6 0.80 0.77–0.83 0.84 0.81–0.88
No chemotherapy 4509 4448 98.6 3.30 3.17–3.44 2.64 2.52–2.76
Trust first seen
Non-chemotherapy trust 4276 4011 93.8 1.00 1.00
Chemotherapy trust 10 779 10171 94.4 1.01 0.97–1.04 0.99 0.95–1.02
Missing/trust that saw
o20 cases
36 33 91.7 0.99 0.70–1.39 0.93 0.66–1.32
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; NLCA¼National Lung Cancer Audit.
aAdjusted for sex, age, performance status, co-morbidity index and stage.
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chemotherapy trusts treat a greater proportion of patients but that
this does not show a survival benefit requires further work to
clarify the reasons, but it may be that better selection of patients for
treatment and continuation of treatment is a key.
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